For research use only. Not for therapeutic Use.
TTP 22（Cat No.:I003181）is a small-molecule inhibitor that targets the Wnt/β-catenin signaling pathway, which plays a crucial role in cell proliferation, differentiation, and stem cell renewal. By inhibiting this pathway, TTP 22 disrupts β-catenin-mediated transcription, leading to reduced cell proliferation, especially in cancer cells that rely on aberrant Wnt signaling. This compound is of significant interest in cancer research, particularly for tumors with dysregulated Wnt activity. TTP 22 is widely used to explore therapeutic strategies in oncology, offering potential for targeting cancers driven by the Wnt/β-catenin pathway.
| Catalog Number | I003181 |
| CAS Number | 329907-28-0 |
| Synonyms | 3-[5-(4-methylphenyl)thieno[2,3-d]pyrimidin-4-yl]sulfanylpropanoic acid |
| Molecular Formula | C16H14N2O2S2 |
| Purity | ≥95% |
| Target | CK2 |
| Solubility | DMSO: ≥ 51 mg/mL |
| Storage | Store at -20°C |
| IC50 | 0.1 uM |
| IUPAC Name | 3-[5-(4-methylphenyl)thieno[2,3-d]pyrimidin-4-yl]sulfanylpropanoic acid |
| InChI | InChI=1S/C16H14N2O2S2/c1-10-2-4-11(5-3-10)12-8-22-16-14(12)15(17-9-18-16)21-7-6-13(19)20/h2-5,8-9H,6-7H2,1H3,(H,19,20) |
| InChIKey | RAOULLCLLOGTDA-UHFFFAOYSA-N |
| SMILES | CC1=CC=C(C=C1)C2=CSC3=C2C(=NC=N3)SCCC(=O)O |
| Reference | </br>1:Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99. Pagani O, Klingbiel D, Ruhstaller T, Nolè F, Eppenberger S, Oehlschlegel C, Bernhard J, Brauchli P, Hess D, Mamot C, Munzone E, Pestalozzi B, Rabaglio M, Aebi S, Ribi K, Rochlitz C, Rothgiesser K, Thürlimann B, von Moos R, Zaman K, Goldhirsch A; Swiss Group for Clinical Cancer Research (SAKK)..Ann Oncol. 2017 Feb 1;28(2):305-312. doi: 10.1093/annonc/mdw622. PMID: 27998961 </br>2:Tristetraprolin regulation of interleukin-22 production. Härdle L, Bachmann M, Bollmann F, Pautz A, Schmid T, Eberhardt W, Kleinert H, Pfeilschifter J, Mühl H.Sci Rep. 2015 Oct 21;5:15112. doi: 10.1038/srep15112. Erratum in: Sci Rep. 2015;5:17160. PMID: 26486958 Free PMC Article</br>3:Ticlopidine-associated ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in 22 persons in Japan: a report from the Southern Network on Adverse Reactions (SONAR). Bennett CL, Jacob S, Dunn BL, Georgantopoulos P, Zheng XL, Kwaan HC, McKoy JM, Magwood JS, Qureshi ZP, Bandarenko N, Winters JL, Raife TJ, Carey PM, Sarode R, Kiss JE, Danielson C, Ortel TL, Clark WF, Ablin RJ, Rock G, Matsumoto M, Fujimura Y.Br J Haematol. 2013 Jun;161(6):896-8. doi: 10.1111/bjh.12303. Epub 2013 Mar 27. No abstract available. PMID: 23530950 Free PMC Article</br>4:Response to plasmapheresis in myasthenia gravis patients: 22 cases report. Yazdi MF, Baghianimoghadam M, Nazmiyeh H, Ahmadabadi AD, Adabi MA.Rom J Intern Med. 2012 Jul-Sep;50(3):245-7. PMID: 23330293 </br>5:Prolonged inhibition of von Willebrand factor-cleaving protease after splenectomy in a 22-year-old patient with acute and plasma refractory thrombotic thrombocytopenic purpura. Langer F, Bergmann F, Budde U, Hegewisch-Becker S, Hossfeld DK.Br J Haematol. 2002 Jul;118(1):271-4. PMID: 12100160 </br>6:[Thrombocytopenic thrombotic purpura. Retrospective study of 22 consecutive occurrences in 16 patients]. Blanco A, Palacio C, López A, Acebedo G, Castellá D, Juliá A.Med Clin (Barc). 1998 Oct 3;111(10):385-8. Spanish. PMID: 9833242 </br>7:[Clinical demonstrations: 1. Renal tubular acidosis; 2. Breast neoplasm with bone metastases in a man; 3. Thrombotic thrombocytopenic purpura; 4. Precocious eclampsia in a 22 years old primipara]. Weber J.Schweiz Med Wochenschr. 1977 Dec 10;107(49):1808-19. French. PMID: 563099 |
